Solos Endoscopy, Inc.
www.solosendoscopy.com
(OTCPK: SNDY)

September 23, 2015

Dear Solos Endoscopy, Inc. Shareholders,

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an update as our Company moves forward with our plans for restructuring.

Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the treatment and management of diseases for over 25 years. The company offers over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

Management believes the current market capitalization of Solos Endoscopy stock does not truly reflect the value of the Company. Despite being one of the few micro cap medical device Companies with both FDA and ISO certifications, Solos Endoscopy stock price has remained very low. It is for this reason; the Board of Directors has approved a one thousand five hundred to one (1500 to 1) reverse stock split of the Corporation's common stock.

Despite our previous communication with you, whereby the Board of Directors approved the Reverse Split with a record date of September 28, 2015, the company received Notice today from FINRA that the Market Effective Date will be 9/24/2015. Please note that with a reverse split our stock symbol (SNDY) will now have a "D" on it for the next 20 business days. The new symbol will be SNDYD.


It is our hope that the recapitalization of the Company will give the market an opportunity to recognize the value of Solos Endoscopy. Solos is a Company who has been recognized by physicians who use their instruments Nationwide. In 2014, Solos Endoscopy received its ISO 13485:2003 Certification from TUV SUD America. The Certification to ISO 13485:2003 allows Solos Endoscopy to place the CE Mark on the majority of its endoscopic instruments including the MammoView® devices. All Solos Endoscopy's instruments are FDA approved.

As a result of Solos Endoscopy's poor capital structure over the past year, the Company has not been able to raise sufficient capital to properly effectuate its business plan. The Company has experienced significant back orders in 2014 and 2015 due to supply issues, and management has not had the funding necessary to pursue plans to market its instruments internationally. Management continues to work with its suppliers in an effort to resolve outstanding issues regarding production.

As mentioned above, the recapitalization is an effort by management to give the market an opportunity to recognize the value of our Company and rebuild shareholder value.

Solos Endoscopy, as a public Company, will continue to update its shareholders through regular postings on www.otcmarkets.com and through Company press releases. To learn more information about the Company and its products visit www.solosendoscopy.com. I want to thank all our loyal shareholders and I look forward to success in the future. To learn more information about the Company and its products visit www.solosendoscopy.com. I want to thank all our loyal shareholders for their continued support.

Regards,



Robert Segersten
President and CEO
Solos Endoscopy, Inc.

Certain statements in this document may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this document, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.